FDA flags neurosurgical shortage through 2026
Supply Chain Pulse — 2026-05-08
The FDA is warning of critical shortages in neurosurgical pads and sponges expected to persist through 2026, forcing OR teams to scramble for alternatives just as patient volumes recover. Meanwhile, CMS and FDA are fast-tracking a new pathway to accelerate Medicare coverage for breakthrough devices, and BD is raising revenue forecasts on strong portfolio performance. It's a tale of two supply chains: acute shortages in basic consumables while innovation accelerates through regulatory pipelines.
Quick Hits
- Radiotherapy expands beyond cancer treatment to osteoarthritis, opening new revenue streams (Modern Healthcare)
- Health systems redesign care teams around advanced practice providers and pharmacists (Modern Healthcare)
- New research confirms antimicrobial stewardship programs reduce drug usage and improve outcomes (Healthcare Purchasing News)
- CPKC and CSX launch faster rail route connecting Southeast U.S. to Mexico (Supply Chain Dive - Healthcare)
- Hospital-at-home providers push states to expand Medicaid coverage for scaling programs (Modern Healthcare)
FDA warns of neurosurgical supply shortage lasting through 2026
The FDA has flagged critical shortages of neurosurgical pads and sponges that are expected to disrupt operations through 2026. This hits neurosurgery departments particularly hard, as these specialized products have limited substitutes and sourcing alternatives often requires lengthy clinical evaluations. Supply chain teams should immediately audit current inventory levels and establish backup supplier relationships for affected product categories.
CMS, FDA launch RAPID pathway for breakthrough device coverage
CMS and FDA unveiled a new process to accelerate Medicare coverage for breakthrough medical devices by involving CMS in clinical trial design from the start. This could significantly reduce the traditional 12-24 month gap between FDA approval and Medicare coverage decisions, making it easier for hospitals to justify early adoption of innovative technologies. Expect faster patient access and potentially earlier revenue opportunities for cutting-edge devices.
BD raises FY26 revenue outlook on strong portfolio performance
BD lifted its fiscal 2026 revenue guidance, reversing earlier cuts made after selling its diagnostics division to Waters. The medical device giant's recovery signals stabilizing demand across core product lines, which could translate to more predictable pricing and availability for hospitals relying on BD's extensive supply portfolio. This is particularly relevant for supply chain managers tracking vendor financial health and supply security.
Source: Medical Device Network
Cross Country Healthcare going private in $437M Knox Lane deal
Staffing giant Cross Country Healthcare will be acquired by private equity firm Knox Lane for $437 million, with the deal expected to close in Q3. This consolidation in the healthcare staffing market could impact contract pricing and availability for hospitals already struggling with workforce shortages. Supply chain leaders should monitor how this affects their organization's staffing vendor relationships and costs.
Advocate Health plans hospital-at-home expansion across 69 facilities
Advocate Health is scaling its hospital-at-home program system-wide across all 69 hospitals, creating massive new demand for home-based medical equipment and supplies. This represents one of the largest commitments to hospital-at-home services by a major health system, signaling a significant market shift. Supply chain teams should prepare for increased demand in portable monitoring devices, home infusion supplies, and remote care technologies.
Trade court rules Trump's 10% global tariff illegal
The U.S. Court of International Trade declared Trump's 10% global tariff "unauthorized by law," though it only provided injunctive relief for specific parties rather than a universal stay. While this creates uncertainty about tariff enforcement, supply chain managers should continue contingency planning for potential cost increases on imported medical devices and supplies. The ruling doesn't eliminate tariff risk entirely.
Source: Supply Chain Dive - Healthcare
Novartis breaks ground on fifth U.S. radiopharmaceutical facility in Texas
Novartis began construction on a new radioligand therapy manufacturing center in Texas, marking its fifth such facility in the U.S. This expansion addresses growing demand for specialized cancer treatments and improves regional supply chain access for hospitals offering these therapies. The facility should reduce shipping complexities for these time-sensitive, temperature-controlled products.
Source: Pharmaceutical Business Review
Study questions $7.8B spent by nonprofits on management consultants
A JAMA study revealed nonprofit hospitals spent $7.8 billion on management consulting services from 2009-2023, raising questions about ROI and resource allocation. With mounting financial pressures, this data could influence board-level scrutiny of consulting spend, including supply chain optimization projects. Expect increased pressure to demonstrate measurable outcomes from external consulting engagements.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe